Title: Staphylococcus saprophyticus: Which beta-lactam? - ScienceDirect
Headings: Staphylococcus saprophyticus
: Which beta-lactam?

International Journal of Infectious Diseases
Short Communication
Staphylococcus saprophyticus: Which beta-lactam?
Highlights
Abstract
Background
Methods
Results
Conclusions
Keywords
Introduction
Methods
Results
Discussion
Conflict of interest/funding
References

Content: ThermoScientific) for both the MSSS and MSSA isolates. The results were interpreted according to the EUCAST recommendations ( http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_7.1_Breakpoint_Tables.pdf ). Results
The 85 MSSS were mainly isolated from urine samples (98.8%). Among these urine samples, 96.4% were collected from female patients. Most patients (83.3%) were between 16 and 30 years old. Most urine samples (92.8%) were collected in the emergency departments of the hospital. Leukocyte counts in the urine >104/ml and the presence of Gram-positive cocci were recorded for most of the urine samples infected with MSSS (92.8% and 65.9%, respectively). The clinical symptoms recorded for the patients corresponded to cystitis (59.5%), pyelonephritis (33.3%), abdominal pain (6.0%), and prostatitis (1.2%). Finally, the empirical antibiotic therapy administered to the patients was analysed. In this study, 60% of patients with a diagnosis of cystitis were given an inappropriate antibiotic regimen (cefixime, fosfomycin, or amoxicillin), whereas the rate was 25% for those with a diagnosis of pyelonephritis (amoxicillin and cefixime).